Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 228,253
  • Shares Outstanding, K 85,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,520 K
  • EBIT $ -57 M
  • EBITDA $ -57 M
  • 60-Month Beta 0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.94

Options Overview Details

View History
  • Implied Volatility 264.73% (+13.88%)
  • Historical Volatility 61.82%
  • IV Percentile 73%
  • IV Rank 32.86%
  • IV High 645.74% on 04/03/25
  • IV Low 78.27% on 08/06/25
  • Expected Move (DTE 12) 1.17 (43.77%)
  • Put/Call Vol Ratio 0.57
  • Today's Volume 3,064
  • Volume Avg (30-Day) 1,958
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 46,036
  • Open Int (30-Day) 36,145
  • Expected Range 1.51 to 3.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.21
  • Prior Year -0.19
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.65 +62.42%
on 11/07/25
2.77 -3.25%
on 11/28/25
+0.88 (+48.89%)
since 11/05/25
3-Month
1.65 +62.42%
on 11/07/25
2.77 -3.25%
on 11/28/25
+0.88 (+48.89%)
since 09/05/25
52-Week
0.63 +325.40%
on 04/09/25
2.77 -3.25%
on 11/28/25
+0.83 (+44.86%)
since 12/05/24

Most Recent Stories

More News
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential...

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc . (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization...

MIST : 2.68 (+1.52%)
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.68 (+1.52%)
Milestone® Pharmaceuticals to Present at Upcoming Conferences

MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings...

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST...

MIST : 2.68 (+1.52%)
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

MIST : 2.68 (+1.52%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 2.90
2nd Resistance Point 2.81
1st Resistance Point 2.74
Last Price 2.68
1st Support Level 2.59
2nd Support Level 2.50
3rd Support Level 2.44

See More

52-Week High 2.77
Last Price 2.68
Fibonacci 61.8% 1.95
Fibonacci 50% 1.70
Fibonacci 38.2% 1.45
52-Week Low 0.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar